PIPELINE
Next-generation bispecific antibodies to raise the efficacy bar
At Navigator, we’re advancing a pipeline of expertly engineered bispecific antibodies that combine OX40L inhibition with other potentially synergistic mechanisms to deliver effective, well tolerated and convenient options for people living with complex inflammatory diseases
Hidradenitis suppurativa needs new treatment
Hidradenitis suppurativa or HS, is the first inflammatory disorder we are working to alleviate for patients through our pipeline.
HS is a chronic inflammatory skin condition that causes painful lumps, abscesses, and scarring to develop in areas where skin often rubs together like armpits, groin and under the breasts. When hair follicles become blocked, inflammation can start and deep, painful nodules can develop that eventually rupture and drain fluid. People with HS often experience symptom flare-ups that can significantly impact daily activities and their quality of life.
Over one million people in the U.S. live with moderate-to-severe HS which affects three times more women than men. Today, in the absence of effective treatment many patients experience delayed diagnosis and only 350,000 currently seek treatment, with many people struggling to manage their symptoms for years. The visible nature of the condition and its impact on intimate areas can profoundly affect self-esteem, relationships, and overall mental health, underscoring the critical need for effective new options.
Expanded Access Policy
Navigator Medicines, Inc. is developing therapies that have the potential to transform the lives of patients suffering from inflammatory disorders and autoimmune diseases. We are committed to bringing these important and innovative therapies to patients, while collaborating with patients, families, patient advocacy organizations, physicians, researchers, and regulatory authorities to accomplish this goal.
We understand that patients and families may be interested in accessing Navigator Medicines’ investigational therapies prior to regulatory approval and outside of the clinical trial setting through an expanded access program (sometimes referred to as “compassionate use” or “early access”). At this time, we do not have an expanded access program that allows patients to have access to our investigational products prior to FDA approval.
Navigator Medicines believes that participation in robust, thoughtfully designed clinical trials is the most effective way for an individual patient to access investigational products. Clinical trials are conducted to gain an understanding of the safety and efficacy of an investigational product, collecting data that may support the approval of a new therapy. We encourage awareness of and participation in our clinical trials. Information regarding our clinical trials may be found on www.clinicaltrials.gov.
Treating physicians, patients, and/or caregivers interested in learning more about Navigator Medicines’ investigational therapies should contact Navigator Medicines at info@NavigatorMeds.com. We anticipate acknowledging receipt of inquiries sent to this email within five business days.